Future studies should focus on dissecting the molecular architecture of the YAP/TAZ–PD-L1 signaling axis and evaluating the biological and clinical significance of this drug combination in the setting of NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.